Journal
AMERICAN JOURNAL OF THERAPEUTICS
Volume 25, Issue 2, Pages E270-E272Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MJT.0000000000000517
Keywords
immune-mediated thrombocytopenia purpura; bortezomib
Categories
Funding
- National Institutes of Health, National Heart, Lung, and Blood Institute [T32HL007149]
Ask authors/readers for more resources
The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available